Oxurion Announces Extraordinary General Shareholders’ Meeting
Oxurion Announces Extraordinary General Shareholders’ Meeting
Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces an extraordinary general shareholders’ meeting to be held on Thursday July 4, 2024 at 11:00 AM (CET).
This extraordinary general shareholders’ meeting regards the proposal of share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share consolidation.
The convening notice and other documents pertaining to the shareholders’ meeting, can be consulted on Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
| Oxurion NV Pascal Ghoson Chief Executive Officer pascal.ghoson@oxurion.com
|
Backstage Communication Jurgen Vluijmans Partner jurgen@backstagecom.be
|
Attachment
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NYnewscast.com takes no editorial responsibility for the same.
